Search results for "Anus"

showing 10 items of 841 documents

Oral lichen planus: a retrospective study of 633 patients from Bucharest, Romania

2012

Objective: In this retrospective study, patients’ medical records were reviewed to investigate the profiles of 633 OLP cases in a group of Romania. Material and Methods: In this retrospective study, the following clinical data were obtained from the medical charts of patients: gender, age, clinical presentation of OLP, site affected, presence of symptoms, extraoral manifestations of lichen planus, presence of systemic diseases, and history of medications. Results: Most (78.67%) OLP patients were female and the mean age at presentation was 52 years. The white type of the disease (reticular/papular/plaque lesions) was the main form encountered in this sample (48.97%). Among patients with avai…

Malemedicine.medical_specialtyHepatitis C virusPopulationGallbladder diseaseOdontologíaDiseasemedicine.disease_causestomatognathic systemmedicineHumanseducationGeneral DentistryAgedRetrospective Studieseducation.field_of_studyOral Medicine and Pathologybusiness.industryRomaniaMedical recordRetrospective cohort studymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgerystomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCholecystitisSurgeryOral lichen planusResearch-ArticleFemalebusinessLichen Planus Oral
researchProduct

Scoring systems for Oral Lichen Planus used by differently experienced raters

2017

BACKGROUND: Scoring systems have been widely used to evaluate the severity and activity of oral lichen planus (OLP). The aim of the present study was to compare two existing (one modified) scoring systems in the evaluation of OLP severity and correlation with pain. Three differently experienced raters were involved. MATERIALS AND METHODS: Consecutive patients with OLP were assessed for pain using the Visual Analogue Scale and examined at 10 intraoral sites before starting (T0) and three weeks after (T1) steroid therapy (Clobetasol). Three differently experienced raters evaluated photographs using two scoring systems designated White-Erosive-Atrophic (WEA) modified from an older WEA system (…

Malemedicine.medical_specialtyIntraclass correlationVisual analogue scalePainraterBuccal mucosaSpearman's rank correlation coefficientSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessOral and maxillofacial pathologymedicineHumansGeneral DentistryGlucocorticoidsUNESCO:CIENCIAS MÉDICASPain MeasurementClobetasolOral Medicine and Pathologybusiness.industryResearchscoring system030206 dentistryMiddle Agedmedicine.diseaseDermatologyWEAstomatognathic diseasesOtorhinolaryngologyOral lichen planu030220 oncology & carcinogenesisClobetasolOral lichen planusSurgeryOral lichen planusFemaleVASbusinessOral lichen planus; scoring system; VAS; REU; WEA; raterREULichen Planus Oral
researchProduct

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

2021

International audience; Introduction: for localized T1N0 squamous cell carcinoma of the anus (SCCA) standard radiotherapy (RT) may result in overtreatment and alternative strategies are debated. Methods: T1N0M0 SCCA treated between 2015 and 2020 by local excision (LE) or RT were analyzed from the French prospective FFCD ANABASE cohort. Treatment strategies, recurrence-free and colostomy-free survivals (RFS, CFS) and prognostic factors were reported. Results: among 1135 SCCA patients, 99 T1N0M0 were treated by LE(n = 17,17.2%), or RT ( n = 82,82.8%) including RT alone ( n = 65,79.2%) or chemo-RT ( n = 17, 20.7%). Median follow-up was 27.2 months [0.03 and ndash;54.44]. Median tumor size were…

Malemedicine.medical_specialtyLocal excisionLocal excisionmedicine.medical_treatmentAnal Canal[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineAgedRetrospective StudiesAged 80 and overUnivariate analysisHepatologyRadiotherapybusiness.industryOptimal treatmentGastroenterologyAnal Squamous Cell CarcinomaChemoradiotherapyMiddle AgedAnusAnus Neoplasms3. Good healthRadiation therapymedicine.anatomical_structureAnal canal carcinoma030220 oncology & carcinogenesisCohortCarcinoma Squamous CellFemaleFrancebusinessChemoradiotherapy
researchProduct

Prognostic evaluation of biofeedback response in patients treated for anorectal malformation

2015

Abstract Purpose Functional bowel outcome in patients with anorectal malformation often is poor. For fecal incontinence resulting from sphincter dysfunction, biofeedback (BFB) training appears to be effective. The aim of study was to investigate the bowel function in incontinent children treated for ARM, using a clinical score, a manometric and pelvic magnetic resonance evaluation, in order to establish predictive parameters of response after BFB. Methods 25 children (median age of 6.5years) with true fecal incontinence were evaluated by clinical score, anorectal manometry and magnetic resonance imaging (MRI). According to these evaluations patients were divided in 4 groups: group 1 (favora…

Malemedicine.medical_specialtyManometrymedicine.medical_treatmentAnal CanalRectumBiofeedbackAnus ImperforateBiofeedback trainingmedicineHumansFecal incontinenceAnorectal malformation; Anorectal manometry; Biofeedback training; Fecal incontinenceChildmedicine.diagnostic_testbusiness.industryGenitourinary systemSettore MED/20 - Chirurgia Pediatrica E InfantileAnorectal manometryRectumBiofeedback PsychologyMagnetic resonance imagingGeneral MedicineAnal canalAnorectal malformationPrognosisMagnetic Resonance ImagingAnorectal manometryAnorectal MalformationsSurgeryTreatment Outcomemedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child HealthSphincterFemaleSurgeryRadiologymedicine.symptombusinessFecal IncontinenceJournal of Pediatric Surgery
researchProduct

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Resul…

2018

Abstract Background and purpose Standard treatment of epidermoid anal cancer is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase I study aims to evaluate the addition of panitumumab (Pmab) to CRT and to determine the maximum tolerated dose (MTD) of Pmab and 5-FU in combination with CRT. Materials and methods Immunocompetent patients with locally advanced tumour without metastases (Stage T2, T3 or T4, whatever N stage; Stage N1–N3 whatever T stage) followed two RT periods (45 Gy in 5 weeks and 20 Gy in 2 weeks, separated by a 2-week break) with concomitant CT sessions of 5FU/MMC at RT weeks 1, 5 and 8. Pmab was administered on RT weeks 1, 3, 5, 8 and 10 ac…

Malemedicine.medical_specialtyMitomycinUrologyPhases of clinical research030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnal cancerPanitumumabRadiology Nuclear Medicine and imagingProspective StudiesAgedbusiness.industryPanitumumabStandard treatmentMitomycin CChemoradiotherapyHematologyMiddle AgedAnus Neoplasmsmedicine.diseaseErbB ReceptorsOncology030220 oncology & carcinogenesisConcomitantT-stageFemaleFluorouracilbusinessChemoradiotherapymedicine.drugRadiotherapy and Oncology
researchProduct

Topical treatment of oral lichen planus with anthocyanins

2014

Background: Oxidative stress is involved in oral lichen planus (OLP) pathogenesis; meanwhile anthocyanins are natural antioxidants present in grapes skin. Objectives: The aim of this research was to verify the utility of anthocyanins, extracted from grapes skin, for the local treatment of oral lichen planus and to compare it with clobetasol propionate- neomycin -nystatin cream (CP-NN). Study Design: Prospective, non-randomized study, with control group. Fifty-two patients with OLP were includ - ed. We divided patients into two categories: erosive oral lichen planus (EOLP) and non erosive oral lichen planus (NEOLP). 38 had EOLP (17 cases and 21 controls) and 14 presented NEOLP types (9 cases…

Malemedicine.medical_specialtyNystatinAdministration TopicalTopical treatmentOdontologíamedicine.disease_causeAnthocyaninsstomatognathic systemmedicineHumansProspective StudiesOral mucosaProspective cohort studyGeneral DentistryClobetasolOral Medicine and Pathologybusiness.industryResearchSignificant differencefungifood and beveragesNeomycinMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgeryDrug Combinationsstomatognathic diseasesmedicine.anatomical_structureNystatinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusFemaleClobetasol propionatebusinessOxidative stressmedicine.drugLichen Planus Oral
researchProduct

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

2009

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5…

Malemedicine.medical_specialtyPathologyLeukocytosismyeloproliferative neoplasm thrombosis jak2GastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeSettore MED/15 - Malattie Del SangueLeukocyte CountPolycythemia verahemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaLeukocytosisRisk factorProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedbusiness.industryEssential thrombocythemiaHazard ratioThrombosisHematologyGeneral MedicineJanus Kinase 2Middle Agedmedicine.diseaseThrombosisMultivariate AnalysisFemalemedicine.symptombusinessThrombocythemia Essential
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct

Mild phenotypes in a series of patients with Opitz GBBB syndrome with MID1 mutations

2004

Contains fulltext : 48815.pdf (Publisher’s version ) (Closed access) Opitz syndrome (OS; MIM 145410 and MIM 300000) is a congenital midline malformation syndrome characterized by hypertelorism, hypospadias, cleft lip/palate, laryngotracheoesophageal (LTE) abnormalities, imperforate anus, developmental delay, and cardiac defects. The X-linked form (XLOS) is caused by mutations in the MID1 gene, which encodes a microtubule-associated RBCC protein. In this study, phenotypic manifestations of patients with and without MID1 mutations were compared to determine genotype-phenotype correlations. We detected 10 novel mutations, 5 in familial cases, 2 in sporadic cases, and 3 in families for whom it …

Malemedicine.medical_specialtyUbiquitin-Protein LigasesBiologymedicine.disease_causeGastroenterologyG/BBB SYNDROMEFAMILIESGenomic disorders and inherited multi-system disorders [IGMD 3]Genotype-phenotype distinctionInternal medicineGeneticsmedicineHumansHypertelorismGeneGenetics (clinical)GeneticsFamily HealthX-linked Opitz syndromeMutationMID1Nuclear ProteinsGenetic Diseases X-LinkedExonsOpitz G/BBB Syndromemedicine.diseasePhenotypeGENEPedigreeSmith-Lemli-Opitz SyndromePhenotypeGenetic defects of metabolism [UMCN 5.1]HypospadiasMutationMicrotubule ProteinsFemalephenotypic variabilityXP22medicine.symptomImperforate anusFunctional Neurogenomics [DCN 2]BBBTranscription FactorsAmerican Journal of Medical Genetics. Part A
researchProduct

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

2007

Drug-eluting stents are increasingly used to reduce in-stent restenosis and adverse cardiac events after percutaneous coronary interventions. However, the race for the ideal drug-eluting stent is still on, with special regard to the best stent-coating system and the most effective and less toxic drug. Fludarabine, a nucleoside analog, has both anti-inflammatory and antiproliferative cellular effects. The aim of the present study was to assess the cellular and molecular effects of fludarabine on vascular smooth muscle cell (VSMC) growth in vitro and in vivo and the feasibility and efficacy of a fludarabine-eluting stent. To study the biomolecular effects of fludarabine on VSMC proliferation…

Malemedicine.medical_specialtyVascular smooth muscleTime FactorsPhysiologyMyocytes Smooth MusclePharmacologyProsthesis DesignTransfectionMuscle Smooth VascularRestenosisIn vivoPhysiology (medical)medicineAnimalsCarotid StenosisRNA AntisensePhosphorylationRats WistarAortaCells CulturedCell ProliferationNeointimal hyperplasiaHyperplasiaDose-Response Relationship Drugbusiness.industryCardiovascular AgentsHyperplasiaJanus Kinase 2medicine.diseaseFludarabineSurgeryRatsDisease Models AnimalSTAT1 Transcription FactorCardiovascular agentSTAT proteinFeasibility StudiesStentsRabbitsCardiology and Cardiovascular MedicinebusinessCarotid Artery InjuriesTunica IntimaAngioplasty BalloonVidarabinemedicine.drug
researchProduct